Cellectis S.A. (NASDAQ:CLLS) Receives $7.00 Consensus Target Price from Analysts

Cellectis S.A. (NASDAQ:CLLS) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $7.00.

Several research analysts have weighed in on CLLS shares. Barclays began coverage on Cellectis in a report on Thursday, May 28th. They set an “overweight” rating and a $9.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $8.00 price objective on shares of Cellectis in a report on Tuesday, April 14th.

Cellectis Stock Performance

Shares of NASDAQ:CLLS opened at $2.77 on Friday. The company has a market capitalization of $277.94 million, a price-to-earnings ratio of -4.13 and a beta of 2.88. The firm’s 50 day simple moving average is $3.14 and its 200 day simple moving average is $3.59. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. Cellectis has a fifty-two week low of $2.00 and a fifty-two week high of $5.48.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.08. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.04 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after acquiring an additional 3,284,409 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Cellectis during the 4th quarter worth about $15,385,000. Citadel Advisors LLC acquired a new stake in shares of Cellectis in the 3rd quarter valued at about $633,000. Marshall Wace LLP raised its stake in shares of Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 168,038 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.